Terms: = Breast cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Diagnosis
204 results:
1. Investigation of Genetic Alterations Associated With Interval breast cancer.
Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
[TBL] [Abstract] [Full Text] [Related]
2. The Potential of Genetics in Identifying Women at Lower Risk of breast cancer.
Bolze A; Cirulli ET; Hajek C; Schnell Blitstein JM; Grzymski JJ
JAMA Oncol; 2024 Feb; 10(2):236-239. PubMed ID: 38153744
[TBL] [Abstract] [Full Text] [Related]
3. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of Complications in Patients With a History of Cannabis Use and Tobacco Use Undergoing Implant-Based breast Reconstruction.
Garoosi K; Lee N; Tuano KR; Lee ELH; Cohen J; Winocour J; Mathes DW; Iorio ML; Kaoutzanis C
Aesthet Surg J; 2023 Dec; 44(1):NP41-NP48. PubMed ID: 37706275
[TBL] [Abstract] [Full Text] [Related]
5. ataxia Telangiectasia in a Patient with breast cancer: A Case Report.
Mizuno M; Ohnuki Y; Unzaki A; Suzuki M; Takeshita K; Takahashi S; Kiyohara H; Nakagawa S; Ishida R; Yokoyama K; Terao M; Okamura T; Hanamura T; Niikura N
Tokai J Exp Clin Med; 2023 Sep; 48(3):95-98. PubMed ID: 37635070
[TBL] [Abstract] [Full Text] [Related]
6. Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Hequet D; Hajjaji N; Charafe-Jauffret E; Boucrauta A; Dalenc F; Nicolai V; Lopez J; Tredan O; Deluche E; Fermeaux V; Tixier L; Cayre A; Menet E; Lerebours F; Rouzier R
Cancer Med; 2023 Aug; 12(16):16889-16895. PubMed ID: 37409516
[TBL] [Abstract] [Full Text] [Related]
7. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.
Oropeza E; Seker S; Carrel S; Mazumder A; Lozano D; Jimenez A; VandenHeuvel SN; Noltensmeyer DA; Punturi NB; Lei JT; Lim B; Waltz SE; Raghavan SA; Bainbridge MN; Haricharan S
Sci Adv; 2023 Jun; 9(26):eadf2860. PubMed ID: 37390209
[TBL] [Abstract] [Full Text] [Related]
8. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
9. Educational differences in healthcare use among survivors after breast, prostate, lung, and colon cancer - a SEQUEL cohort study.
Levinsen AKG; Kjaer TK; Maltesen T; Jakobsen E; Gögenur I; Borre M; Christiansen P; Zachariae R; Laurberg S; Christensen P; Kroman N; Larsen SB; Degett TH; Hölmich LR; Brown PN; Johansen C; Kjær SK; Thygesen LC; Dalton SO
BMC Health Serv Res; 2023 Jun; 23(1):674. PubMed ID: 37349718
[TBL] [Abstract] [Full Text] [Related]
10. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
[TBL] [Abstract] [Full Text] [Related]
11. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
[TBL] [Abstract] [Full Text] [Related]
12. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
[TBL] [Abstract] [Full Text] [Related]
13. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
[TBL] [Abstract] [Full Text] [Related]
14. diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and atm Gene Mutations.
Fencer MG; Krupa KA; Bleich GC; Grumet S; Eladoumikdachi FG; Kumar S; Kowzun MJ; Potdevin LB
Clin Breast Cancer; 2023 Jun; 23(4):e194-e199. PubMed ID: 36966080
[TBL] [Abstract] [Full Text] [Related]
15. MRI phenotypes associated with breast cancer predisposing genetic variants, a multisite review.
Maimone S; Harper LK; Mantia SK; Advani PP; Hochwald AP; Li Z; Hines SL; Patel B
Eur J Radiol; 2023 May; 162():110788. PubMed ID: 36948059
[TBL] [Abstract] [Full Text] [Related]
16. Effectiveness and tasks of breast MRI surveillance for high-risk women with cancer susceptibility genes other than BRCA1/2: a single institution study.
Kikuchi M; Gomi N; Ueki A; Osako T; Terauchi T
Breast Cancer; 2023 Jul; 30(4):577-583. PubMed ID: 36897545
[TBL] [Abstract] [Full Text] [Related]
17. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
18. The impact of coding germline variants on contralateral breast cancer risk and survival.
Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
[TBL] [Abstract] [Full Text] [Related]
19. Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms.
Li C; Dong X; Yuan Q; Xu G; Di Z; Yang Y; Hou J; Zheng L; Chen W; Wu G
J Endocrinol Invest; 2023 Aug; 46(8):1633-1650. PubMed ID: 36725810
[TBL] [Abstract] [Full Text] [Related]
20. Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1).
Roser E; Harter P; Zocholl D; Denschlag D; Chekerov R; Wimberger P; Kurzeder C; Hasenburg A; Muallem MZ; Mustea A; Emons G; Zeimet AG; Beck F; Arndt T; Brucker SY; Kommoss S; Heitz F; Welz J; Egger EK; Kalder M; Buderath P; Klar M; Marth C; Ulrich UA; Weigel M; Traub L; Anthuber C; Strauss H; Hanker L; Link T; Kubiak K; Melekian B; Hornung D; Pölcher M; Lampe B; Krauß T; Keilholz U; Flörcken A; Pietzner K; Sehouli J
Int J Gynecol Cancer; 2023 Feb; 33(2):223-230. PubMed ID: 36631151
[TBL] [Abstract] [Full Text] [Related]
[Next]
